553 results on '"Sicras-Mainar, Antoni"'
Search Results
2. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection/Uso concomitante de antivirales de accion directa (AAD) y farmacos con accion sobre el sistema nervioso central: Consideraciones en el perfil actual del paciente con hepatitis C
3. Disease burden and costs for patients with hip and knee osteoarthritis and chronic moderate-to-severe refractory pain on treatment with strong opioids in Spain
4. Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain
5. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain
6. Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary
7. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study
8. Epidemiología y tratamiento de la insuficiencia cardiaca en España: estudio PATHWAYS-HF
9. Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study
10. The CNIC-Polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischemic heart disease
11. Epidemiology and costs of depressive disorder in Spain: the EPICO study
12. Overall clinical and economic impact of non-alcoholic fatty liver disease
13. Enoxaparina en el tratamiento de la tromboembolia venosa: estudio observacional de práctica clínica habitual
14. Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
15. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
16. Disease Burden and Costs in Moderate-to-Severe Chronic Osteoarthritis Pain Refractory to Standard of Care: Ancillary Analysis of the OPIOIDS Real-World Study
17. Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective Study
18. Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España
19. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
20. Uncontrolled diabetes and health care utilisation: panel data evidence from Spain
21. Comorbilidad, medicación concomitante, uso de recursos y costes sanitarios asociados a los pacientes portadores del virus de la hepatitis C crónica en España
22. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus : A National Health System Perspective
23. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
24. Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA.
25. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus
26. Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
27. P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C
28. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
29. Table_1_Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study.docx
30. Polypharmacyand prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three European countries
31. Economic Impact of Heart Failure According to the Effects of Kidney Failure
32. Uso concomitante de antivirales de acción directa (AAD) y fármacos con acción sobre el sistema nervioso central: Consideraciones en el perfil actual del paciente con hepatitis C
33. The influence of obesity and overweight on medical costs: a panel data perspective
34. Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
35. IDDF2022-ABS-0242 Risk of multiple drug interactions potentially linked to safety in patients receiving pangenotypic direct-acting antivirals for the treatment of hepatitis C
36. Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
37. Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
38. Effect of Smoking Status on Healthcare Costs and Resource Utilization in Patients with Type 2 Diabetes in Routine Clinical Practice : A Retrospective Nested Case-Control Economic Study
39. Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study.
40. Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: A population study
41. Carga de la enfermedad y costes asociados del asma no grave en adultos en España: análisis de datos de una comunidad representativa
42. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions
43. Use of comedication in patients with hepatitis C and addiction or drug abuse treated with direc-acting antivirals: implication in drug-drug interactions
44. Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals
45. Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three European countries
46. Persistence, Use of Resources and Costs in Patients Under Migraine Preventive Treatment: the PERSEC Study
47. Resource Use and Economic Impact of Patients With Gout: A Multicenter, Population-Wide Study
48. Uso de recursos e impacto económico de los pacientes con gota: estudio multicéntrico de ámbito poblacional
49. Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
50. Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.